title: [Screening biopsies in kidney transplantation: from subclinical acute rejection to chronic allograft lesions].
abstract: Kidney biopsies for screening purposes have the advantage of revealing the early appearance of lesions having a poor prognosis before kidney function is altered. Early screening of subclinical rejections allows preventive treatment of kidney transplantation in patients taking cyclosporine or azathioprine, thus improving their renal function and reducing the incidence of chronic histological lesions. However, this benefit has yet to be demonstrated in patients taking tacrolimus or mycophenolic acid. As for interstitial fibrosis lesions and tubular atrophy, biopsies can screen subclinical immunological lesions or those related to nephrotoxicity of anticalcineurins, which have a negative prognostic value in terms of graft survival. In addition, detection of these lesions could be a very useful criterion of efficacy in clinical studies. Moreover, they could help decide on modifying immunosuppressor treatment and evaluate the therapeutic strategies in patients at risk for humoral rejection. Finally, given the cost of biopsies and the inconvenience for the patient, the question of the timing and the number of screening biopsies is crucial. However, interventional studies evaluating notably immunosuppressor treatment modifications based on histological data are necessary to justify the daily use of screening biopsies.
authors.affiliation: Service de Transplantation Rénale, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France. renaud.snanoudj@nck.aphp.fr
authors.forename: R
authors.initials: R
authors.lastname: Snanoudj
authors.forename: F
authors.initials: F
authors.lastname: Martinez
authors.forename: R
authors.initials: R
authors.lastname: Sberro Soussan
authors.forename: E
authors.initials: E
authors.lastname: Thervet
authors.forename: C
authors.initials: C
authors.lastname: Legendre
mesh_terms: D000208:Acute Disease; D015415:Biomarkers; D001706:Biopsy; D002908:Chronic Disease; D042241:Early Diagnosis; D006084:Graft Rejection / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology; D015337:Multicenter Studies as Topic; D055031:Primary Graft Dysfunction / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D014184:Transplantation, Homologous
chemical_list: D015415:Biomarkers; D007166:Immunosuppressive Agents; D007518:Isoantibodies